ABOUT US
NanoBiotech Pharma is a closely-held Florida LLC founded in 2004. After 25 years of family practice & emergency medicine, the company Founder, Gary S. Mezo, solely invented & personally developed the first nanobiotics and commissioned the first independent clinical trials for NanobacTX & Urobac. History & Transitions: In 1997, Mezo Founded NanobacLabs Pharmaceuticals, a Florida LLC which was later changed to a Delaware C Corporation named Nanobac Pharmaceuticals, Inc. (Nanobac). Mezo then acquired from the government of Finland, Nanobac OY, it's scientists, it's patents and it's employees. Mezo then reverse-merged Nanobac Pharmaceuticals to become a US public company. After taking Nanobac Pharmaceuticals public, Mezo retired as Nanobac Pharmaceuticals' Chairman & CEO in 2003. Subsequently, Nanobac Pharmaceuticals, Inc. materially defaulted in it's License & Trademark Agreements with Mezo, and Mezo subsequently founded NanoBiotech Pharma in 2004.
THE NANOBIOTICS:
NanobacTX, The first Nanobiotic. Solely invented by Mezo in 1996, NanobacTX was reverse-engineered to specifically target and dissolve calcified atherosclerotic plaque in Coronary Artery Disease. NanobacTX has been shown in published clinical studies to reverse (dissolve) coronary artery plaque, decrease the associated inflammation & eradicate plaque calcification. NanobacTX was also shown to decrease LDL, decrease homocystiene levels and to improve patient's cardiac symptoms including exercise capacity, while decreasing or eliminating chest pain.
Urobac was designed by Mezo to effectively treat nephrolithiasis (kidney stones), polycystic kidney disease (PKD), benign prostatic hypertrophy (BPH) and chronic prostatitis. Urobac clinical studies, showing efficacy & safety profiles were conducted by prominent urologist/prostatitis researcher, Daniel Shoskes, MD (Cleveland Clinic) and were published in the The Journal of Urology. Additional published Urobac studies were conducted by NASA, Baylor, Mayo, UCSF & others.
Dermabac was developed by Mezo in response to studies done by dermatological pathology researcher, Rauno Harvima, MD, PhD at the University of Kuopio, Finland, where Dr. Harvima isolated CNPs from 100% of his biopsied samples from eczema, psoriasis and atopic dermatitis patients. Dermabac is a therapy targeted to specifically address the pathological calcification & inflammation associated with scleroderma, eczema, psoriasis, atopic dermatitis and calcinosis cutis.
Mezo's Pipeline of nanobiotics and applications continues to grow. Research continues to bolster our scientific position that all pathological calcification is infectious in origin and secondary to infection by CNPs (nanobacteria). Research continues at renowned research facilities worldwide further describing CNPs, pathological calcification and CNP involvement in many chronic diseases. Beside the obvious tissue calcifications and CNPs, we also find a continuum of waxing & waning inflammation, biofilms, endotoxin and plaque (bAmyloid-type scarring) deposition. Eradicating the cause of these associated diseases is our goal. The existing "status quo" of medical care & symptom-control medicines exists to treat symptoms and not the underlying causation. Curing the disease process would obviate the need for symptom-control medicines and for ongoing medical visits.
NanobacTX, Urobac & Dermabac are only available directly from NanoBiotech Pharma and cannot be obtained from any person or pharmacy. If someone other than us says they have NanobacTX, Urobac or Dermabac, it is an illegal knockoff and it is not NanobacTX, Urobac or Dermabac.
[ INTELLECTUAL PROPERTY (IP) RIGHTS: Since sole invention by Gary S. Mezo in 1996, the IP rights to these and all Mezo's nanobiotics (NanobacTX, Urobac, Dermabac, et al) have never been sold or permanently assigned to any Person, Entity, Company or Corporation and were always solely retained by Mezo. As Founder/Chairman/CEO of NanobacLabs Pharmaceuticals (later name-changed to Nanobac Pharmaceuticals), Mezo licensed his nanobiotics to NanobacLabs Pharmaceuticals (aka Nanobac Pharmaceuticals) under a License & Trademark Agreement which required fiscal performance by Nanobac. After Mezo's retirement, Nanobac subsequently materially defaulted on the License & Trademark Agreement in 2003-2004, causing Nanobac to permanently lose all usage rights to any of Mezo's IP. ]